Table I.
Current pathogen inactivation technologies, mechanisms, applications and licensing status.
| Manufacturer | Technology | Key mechanisms | Transfusion components | Licensing | Countries |
|---|---|---|---|---|---|
| Cerus | INTERCEPT® | Amotosalen + UVA Light (320–400 nm) | Platelets (apheresis or whole blood-derived) | CE marked (class III) 2002 | 22 |
| INTERCEPT® | Amotosalen + UVA Light (320–400 nm) | Plasma (apheresis or whole blood-derived) | CE marked (class III) 2006 | 13 | |
| INTERCEPT® | S-303 (FRALE) | Red cells | n/a | - | |
| INTERCEPT® | S-303 (FRALE) | Whole blood | n/a | - | |
|
| |||||
| Terumo BCT | Mirasol® | Riboflavin + UVB Light (280–360 nm) | Platelets (apheresis or whole blood-derived) | CE marked (class IIB) 2007 | 18 |
| Mirasol® | Riboflavin + UVB Light (280–360 nm) | Plasma (apheresis or whole blood-derived) | CE marked (class IIB) 2008 | 11 | |
| Mirasol® | Riboflavin + UVB Light (280–360 nm) | Whole blood | CE marked 2015 | - | |
|
| |||||
| Macopharma | THERAFLEX® | UVC light | Platelets | CE marked (class IIB) 2009 | - |
| THERAFLEX® | Filtration + Methylene Blue + visible light (400–700 nm) | Fresh frozen plasma (apheresis or whole blood-derived) | CE marked (class III) 2004 | 15 | |
|
| |||||
| Octapharma | Octaplas (S/D) | Solvent/Detergent | Large-pool of plasma (apheresis or whole blood-derived) | Licensed (in UK) 1998 | 32 |
|
| |||||
| VIPS | n/a | Solvent/Detergent | Single donation or mini-pool of plasma (apheresis or whole blood-derived) | CE marked 2009 | At least 3 |
|
| |||||
| Vitex | INACTINE | PEN 110 | Red cells | n/a | - |
n/a: not available; UVA/B/C: ultraviolet A/B/C.